Technology in Cancer Research & Treatment (Oct 2024)

First-In-DOg HISTotripsy for Intracranial Tumors Trial: The FIDOHIST Study

  • Christina Vezza DVM,
  • Lauren Ruger PhD,
  • Maya Langman MD,
  • Elliana Vickers,
  • Francesco Prada MD,
  • Jonathan Sukovich PhD,
  • Timothy Hall PhD,
  • Zhen Xu PhD,
  • Rell L. Parker DVM, PhD,
  • Eli Vlaisavljevich PhD,
  • John H. Rossmeisl DVM

DOI
https://doi.org/10.1177/15330338241285158
Journal volume & issue
Vol. 23

Abstract

Read online

Objective Brain tumors represent some of the most treatment refractory cancers, and there is a clinical need for additional treatments for these tumors. Domesticated dogs are the only other mammalian species which commonly develop spontaneous brain tumors, making them an ideal model for investigating novel therapies. Histotripsy is a non-thermal ultrasonic ablation method that emulsifies tissue through acoustic cavitation. The primary objectives of this prospective study were to assess the feasibility and safety of histotripsy to ablate naturally occurring canine brain tumors. Secondary endpoints included characterization of magnetic resonance imaging (MRI) responses to histotripsy treatment, and exploratory immunogenomic tumor response analyses. Methods The study design utilized a treat and resect paradigm, where tumors were approached using craniotomy, partially ablated with histotripsy delivered through the cranial defect, imaged with MRI, and then resected. Dogs were evaluated with clinical, brain MRI, immunopathologic, and genomic examinations before treatment, intraoperatively, and 1, 14, and 42 days post-treatment. Here we report the results of the three dogs with meningiomas, all of which were treated with a custom eight element 1 MHz histotripsy transducer at a pulse repetition frequency of 100 Hz and a treatment dosage of 400 pulses/point. Results Histotripsy was successfully delivered to all dogs, resulting in histopathologic evidence of ablations that were sharply demarcated from untreated tumor, with measured treatments approximating planned volumes in 2/3 dogs. One dog experienced an adverse event consisting of transient cerebral edema that was possibly attributable to histotripsy. Histotripsy ablations could be grossly visualized and identified on MRI, with features consistent with hemorrhage and necrosis. Significant expression or upregulation of the damage associated molecular pattern HMGB1, cytokine-cytokine receptor interaction, and NF-κb signaling pathways were observed in histotripsy treated tumors. Conclusion Ablation of canine meningiomas with histotripsy through an open cranial window was feasible and clinically well tolerated.